Walleye Capital LLC Ascendis Pharma A/S Call Options Transaction History

Walleye Capital LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$113.0 - $153.43 $124,300 - $168,773	-1,100 Reduced 55.0%	900 $134,000
Q2 2024 Aug 14, 2024	SELL	$121.07 - $153.67 $121,070 - $153,670	-1,000 Reduced 33.33%	2,000 $272,000
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $296,280 - $382,560	2,400 Added 400.0%	3,000 $453,000
Q4 2023 Feb 14, 2024	SELL	$86.1 - $127.36 $111,929 - $165,568	-1,300 Reduced 68.42%	600 $75,000
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $60,550 - $72,779	-700 Reduced 26.92%	1,900 $177,000
Q2 2023 Aug 14, 2023	SELL	$69.96 - $97.84 $209,879 - $293,520	-3,000 Reduced 53.57%	2,600 $232,000
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $94,410 - $114,102	-900 Reduced 13.85%	5,600 $600,000
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $318,144 - $422,304	3,200 Added 96.97%	6,500 $793,000
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $277,299 - $363,759	3,300 New	3,300 $341,000

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.